Estimates Revisions Denali Therapeutics Inc.
Stocks
DNLI
US24823R1059
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 22/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 24.92 USD | -0.12% |
|
+2.13% | +50.94% |
| 03:19pm | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| 08-07 | UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- DNLI Stock
- Consensus Denali Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
